Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The special purpose acquisition company, which has listed the units and is beginning to trade on the Nasdaq Capital Market, expects the proposed deal to command a market value of close to $500 million.
Starting with $30 million in seed financing in April, Taysha sprinted through a $95 million Series B in August and rounded the corner this Thursday to bring in $157 million for its IPO.
Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.
Novus Therapeutics announced on Monday that it had completed its acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company.
Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC).
The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.
Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.